Rev Therapeutics is a company based out of California, United States.  Rev Therapeutics has an experienced team developing KREV-202, a patent protected prodrug of CC_930, tanzisertib) to prophylactically treat cardiac surgery associated acute kidney injury. In new published article, David Nikolic-Paterson and team from Monash University found that compared to the vehicle group, treatment with KRev-202 or CC-930 improved the recovery of tubular structure on day 7 and substantially reduced the development of renal fibrosis on day 21, demonstrating the importance of early blockade of the JNK pathway, and concluded "KRev-202 is a new water-soluble JNK inhibitor with therapeutic potential for
preventing ischemia-induced AKI." DOI 10.3389/fphar.2025.1667221

Rev Therapeutics

Org chart

Teams

Offices